Cargando…
Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that sits in the top 10 leading causes of death in the world today and is the current leading cause of death among infectious diseases. Although there is a licensed vaccine against TB, the Mycobacterium bovis bacil...
Autores principales: | Franco, Ana Rita, Peri, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824815/ https://www.ncbi.nlm.nih.gov/pubmed/33466444 http://dx.doi.org/10.3390/cells10010078 |
Ejemplares similares
-
Cleaner synthesis of preclinically validated vaccine adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023) -
Overcoming Challenges
in Chemical Glycosylation to
Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity
por: Romerio, Alessio, et al.
Publicado: (2023) -
Liposomal delivery system/adjuvant for tuberculosis vaccine
por: Moradi, Melika, et al.
Publicado: (2023) -
Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity
por: Stewart, Erica, et al.
Publicado: (2019) -
Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications
por: Gyu Choi, Han, et al.
Publicado: (2023)